SMARCAL1: a new target for taming tumor immune evasion

The viability and development of cancer cells depend on their ability to effectively evade the surveillance of the immune system.To achieve this, cancer cells alter the expression or function of specific molecules to become "invisible".In a recent elegant study in Cell, Leuzzi et al. 1 unveiled a novel player in the intricate game of tumor immune evasion: SMARCAL1, linked to DNA repair, emerges as a dual regulator with a surprising ability to modulate both innate immune signaling and PD-L1 expression.This work not only sheds light on the complex interplay between DNA damage response, innate immunity, and immune checkpoint regulation, but also identifies a potential new target for cancer immunotherapy.Using a CRISPR-Cas9 screen, the authors identified SMARCAL1 as one of the sgRNA-targeted genes that are distinctly enriched in IRF3 High /PD-L1 Low cells (Figure 1A).Interferon regulatory factor 3 (IRF3) is a central signaling mediator of the innate immune signaling pathway, selected as a screening factor.In the innate immunity cGAS-STING pathway, abnormally exposed double-stranded DNA (dsDNA) in the cytoplasm binds to cGAS to produce cGAMP. 2 cGAMP binding by STING is activated, recruiting TANK-binding kinase to phosphorylate IRF3 leading to its nuclear translocation and the induction of type I interferons (IFNs), which then triggers the expression of interferon stimulated genes (ISGs) expression to enhance cellular autonomous defense mechanisms.3 Furthermore,